|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
One hundred acromegaly patients on medical therapy (mean age = 47.1 years; SD = 11.96) completed an online preference study evaluating hypothetical patient profiles described in terms of insulin-like growth factor-I (IGF-I) levels, tumor size, comorbid conditions, signs/symptoms, and quality of life (QoL).
|
30627944 |
2019 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An uncontrolled hyperactive GH-IGF-1 axis may play a dominant role in the development of PTC rather than the BRAFV600E mutation in patients with acromegaly.
|
25329702 |
2014 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, routine screening of GD should be considered in women with acromegaly, particularly in those with risk factors for GD and with uncontrolled IGF-1 levels before pregnancy.
|
31520541 |
2019 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The possible role of IGF1 polymorphism on susceptibility to acromegaly remains to be investigated.
|
25370837 |
2014 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Suppressor of cytokine signaling (SOCS) 2, a negative regulator of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), which is associated with acromegaly and cancers, is a promising candidate molecule for treating various diseases.
|
30343638 |
2019 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Extent of treatments given for acromegaly associated with higher preoperative GH (P = 7.94 × 10<sup>-4</sup>), KNOSP (P = 0.003) and preoperative hypopituitarism (P = 0.03) and remission at last follow-up with change in 3-month postoperative IGF1 (P = 2.07 × 10<sup>-7</sup>).
|
27998919 |
2017 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A retrospective observational study was conducted in patients with acromegaly to analyze IGF1 and IGFBP3 gene polymorphisms.
|
25385818 |
2015 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to test whether the relationship between GH and insulin-like growth factor-1 (IGF-1) concentrations is influenced by the GHR genotype in patients with acromegaly.
|
17573420 |
2007 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that this association (i.e.Beckwith-Wiedemann syndrome and acromegaly) is independent, and point out that IGF I and II might be very high in the Beckwith-Wiedemann fetus.
|
8838774 |
1996 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
HF and HD LAN-ATG regimens are effective in normalizing IGF-I values in about one-third of patients with active acromegaly inadequately controlled by long-term conventional SRLs therapy.
|
28419317 |
2017 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Treatment for acromegaly patients with long-acting somatotropin release-inhibiting factor (LA-SRIF) often does not result in complete normalization of IGF-1.
|
24937542 |
2014 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the pathophysiology of endothelial dysfunction in the condition of GH and IGF-1 excess remains a crucial area of investigation to fully dissect the association of acromegaly with cardiovascular disease complications.
|
31396153 |
2019 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The mean age of the 30 acromegaly patients (M/F:14/16) was 47.26 ± 12.52 years (range: 18-64 years) and that of the healthy volunteers (M/F: 17/13) was 44.56 ± 10.74 years (range: 19-62 years).Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels were measured using an electrochemiluminescence method, and serum sclerostin levels using an enzyme-linked immunosorbent assay.The Mann-Whitney U test was used to compare sclerostin levels between the two groups.
|
31821453 |
2020 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As far as polymorphic variants of SST genes are concerned, a possible role of SST5 C1004T and T-461C alleles in influencing GH and IGF-I levels in patients with acromegaly has been proposed.
|
17913341 |
2008 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IGF(CA)19 and IGFBP-3-202A/C gene polymorphism in patients with acromegaly.
|
20920870 |
2010 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Twenty-six patients with active acromegaly (IGF-I >130% upper limit of normal) were randomised to subcutaneous ATL1103 200 mg either once or twice weekly for 13 weeks and monitored for a further 8-week washout period.
|
29789410 |
2018 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?
|
22364960 |
2012 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a disease of exaggerated somatic growth and distorted proportion arising from hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).
|
20234189 |
2010 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Control of acromegaly was defined as a random serum growth hormone (GH) < 1 ng/mL and an age-normalised serum insulin-like growth factor-I (IGF-I) value.
|
28879646 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Background Biochemical control of GH/IGF-I excess in acromegaly (ACRO) is associated with persistent impairment of trabecular microstructure leading to increased risk of vertebral fractures.
|
30640713 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
GH, IGF-1, and Age Are Important Contributors to Thyroid Abnormalities in Patients with Acromegaly.
|
29593792 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Management of acromegaly is particularly challenging in cases where discordant information is obtained from measurement of GH concentrations following oral glucose load and from measurement of IGF-I.
|
28168377 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
A univariate analysis was conducted and eight features, including age, hypertension, ophthalmic disorders, GH, IGF-1, nadir GH, maximal tumor diameter, and Knosp grade, were significantly associated with the TSS response in patients with acromegaly.
|
31673954 |
2020 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Included in this prospective cohort were 41 patients with acromegaly who underwent surgery alone and achieved postoperative normalization of insulin-like growth factor-1.
|
27681883 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, a GH-receptor blocking agent, pegvisomant, was licensed for use in acromegaly and appears to normalise IGF-1 in almost all patients.
|
16262568 |
2005 |